Terms of Use

By using this site or any MetalDrug | Moleculogic service, you affirm that you are of legal age and authorized to enter into this agreement on behalf of yourself or the institution you represent. If you do not agree to these Terms in their entirety, you must immediately cease use of the site and its associated technologies.

Continued access following any update to these Terms constitutes renewed acceptance. Users who hold active NDA status or tiered access credentials are additionally bound by the terms of those executed agreements, which take precedence in the event of conflict with these general Terms.

All content, algorithms, interfaces, molecular logic engines, SEI Reasoning Kernel architecture, design blueprints, entropy scoring frameworks, simulation outputs, and datasets within the MetalDrug | Moleculogic platform are the exclusive intellectual property of MetalDrug | Moleculogic. This includes all MDC and FDC simulations, logic gate schemas, ADMET models, regulatory audit architectures, documentation, and source code.

Blueprints anchored to the ExergyNet L0 cEIP Registry carry cryptographic provenance that constitutes timestamped evidence of authorship. The Merkle hash, genesis hash, and ZK-STARK proof records associated with any blueprint anchored by a named user establish that user's priority claim to that design state within the registry. This provenance does not transfer ownership of the underlying platform logic to the user.

Unauthorized reproduction, reverse-engineering, scraping, distribution, sublicensing, or commercial use of any platform component is strictly prohibited.

Platform tools are permitted for the following uses, calibrated by access tier:

• Tier 0 (Viewer): Public exploration, Blueprint Feed review, AskMo scientific queries, and educational engagement with published compound profiles.
• Tier 1–2 (Researcher): Structured MDC and FDC simulation, blueprint generation and scoring, ExergyNet compute dispatch, Blueprint Ledger anchoring, and pre-regulatory hypothesis development.
• Tier 3–4 (Enterprise): Co-development infrastructure, bulk API access, private compound data export, and licensing integration under separately executed agreements.

Use of SEI-governed simulation outputs in support of IND, NDA, or equivalent regulatory filings requires execution of a separate Regulatory Use License.

Users are solely responsible for safeguarding all access credentials, including passwords, NDA submission identifiers, Ed25519 signing keys, ExergyNet job tokens, and any system-generated identifiers associated with their account.

• Sharing, transferring, or publicly disclosing access credentials is prohibited.
• Uploading falsified molecular data, manipulating entropy scores, or attempting to spoof blueprint hashes or ZK-STARK proof outputs constitutes a material breach.
• Any attempt to circumvent tier-gating logic or interfere with ExergyNet Secure Compute infrastructure may result in immediate account termination and legal action.
• Suspected unauthorized access must be reported promptly to security@metaldrug.com.

Outputs from Moleculogic and all tiered logic simulations are computational in nature — SEI-governed deterministic inferences operating on encoded constraint logic, not independently verified empirical measurements. Each blueprint carries an entropy class (1 = chaotic; 5 = stable) and a confidence score reflecting internal logical stability under defined simulation parameters.

MetalDrug | Moleculogic makes no guarantee of biological efficacy, in vivo pharmacological accuracy, or therapeutic outcome based on simulated results. The platform supplements but does not replace empirical validation under FODAMA 3.0, ICH guidelines, and FDA V&V 40 model credibility frameworks.

The Blueprint Ledger is a Cryptographic Epistemic IP (cEIP) registry. Blueprints are anchored to ExergyNet L0, with settlement proofs on Base L2 (LNES-04) and Solana (LNES-03) via RISC Zero ZK-STARK verification.

• Immutability: Once anchored, genesis hash and timestamp are permanent and cannot be altered or deleted by either party.
• USDC Settlement: Tier 2 anchoring activates a LNES-04 Base L2 USDC settlement event per the applicable licensing agreement. Users are responsible for ensuring adequate credits prior to initiating Tier 2 anchoring.
• Privacy: ZK-STARK architecture ensures prover nodes do not receive plaintext molecular data. However, anchor timestamps, Merkle root hashes, and tier classifications are written to public blockchain records and must be treated as permanently public.
• No Reversibility: MetalDrug | Moleculogic cannot retract or modify any confirmed on-chain transaction. Errors in submitted data are the user's responsibility.

ExergyNet Secure Compute dispatches simulation jobs to a decentralized prover swarm via TLS-encrypted, Ed25519-signed job bundles.

• Data Handling: Prover nodes receive only signed bundles. Plaintext molecular data is not transmitted to or retained by individual prover nodes. ZK proof records are retained by MetalDrug | Moleculogic for audit and reproducibility.
• Pricing: Compute pricing is quoted per-run at session initiation. Published comparisons to hyperscaler providers are based on benchmark heavy virtual screening jobs and may vary by workload. Pricing may be updated with notice.
• Execution: Jobs run asynchronously with a nominal window of 3–15 minutes. Completion times are estimates and not guaranteed under SLA at standard access tiers.
• Credits: Platform compute credits are non-refundable and subject to expiry terms communicated at time of purchase.

MetalDrug | Moleculogic does not warrant that any regulatory output generated by the platform will be accepted by the FDA, EMA, or any other health authority. Users bear sole responsibility for the accuracy, completeness, and regulatory adequacy of any submission in which platform outputs are incorporated.

Any use of platform outputs in an IND, NDA, BLA, or equivalent application requires execution of a Regulatory Use License. Unauthorized regulatory use constitutes a material breach of these Terms.

MetalDrug | Moleculogic services are provided "as-is" and "as-available." No guarantee of uninterrupted access, data loss prevention, or immunity from third-party infrastructure failure is made at standard access tiers. Enterprise-tier SLA provisions are governed by separately executed agreements.

Under no circumstances shall MetalDrug | Moleculogic, its trustees, principals, affiliates, licensors, ExergyNet network operators, or agents be liable for any direct, indirect, incidental, special, or consequential damages arising from the use or inability to use the platform, including without limitation: lost profits from reliance on simulation outputs; data inaccuracies in blueprint or ADMET reports; regulatory rejection of submissions incorporating platform outputs; loss of on-chain assets due to user error; or unauthorized access resulting from failure to secure credentials.

MetalDrug | Moleculogic reserves the right to modify these Terms at any time. Material changes will be communicated via platform notification and reflected in an updated Effective Date. Continued use following any modification constitutes acceptance of the updated Terms.

These Terms shall be governed by and construed in accordance with the laws of the State of South Dakota, United States, without regard to its conflict of law provisions. Any legal proceedings arising from these Terms shall be brought exclusively in the state or federal courts of South Dakota. You consent to personal jurisdiction in those courts and waive any objection to venue.

For questions, legal inquiries, or notices related to these Terms, licensing, regulatory use authorization, or security disclosures: